security

Select Medical Holdings Corporation Announces Results For Its … – PR Newswire


MECHANICSBURG, Pa., Nov. 2, 2023 /PRNewswire/ — Select Medical Holdings Corporation (“Select Medical,” “we,” “us,” or “our”) (NYSE: SEM) today announced results for its third quarter ended September 30, 2023, and the declaration of a cash dividend.

For the third quarter ended September 30, 2023, revenue increased 6.2% to $1,665.7 million, compared to $1,567.8 million for the same quarter, prior year. Income from operations increased 42.1% to $130.0 million for the third quarter ended September 30, 2023, compared to $91.5 million for the same quarter, prior year. For the third quarter ended September 30, 2023, income from operations included $0.5 million of other operating income, compared to $8.4 million of other operating income for the same quarter, prior year. The other operating income for the third quarter ended September 30, 2022, was principally related to the recognition of payments received under the Coronavirus Aid, Relief, and Economic Security Act Public Health and Social Services Emergency Fund, also referred to as the Provider Relief Fund. Net income increased 59.5% to $60.8 million for the third quarter ended September 30, 2023, compared to $38.1 million for the same quarter, prior year. Adjusted EBITDA increased 26.6% to $193.8 million for the third quarter ended September 30, 2023, compared to $153.1 million for the same quarter, prior year. Earnings per common share increased 75.8% to $0.38 for the third quarter ended September 30, 2023, compared to $0.21 for the same quarter, prior year. Adjusted earnings per common share increased 113.7% to $0.46 for the third quarter ended September 30, 2023, compared to $0.21 for the same quarter, prior year. Adjusted earnings per common share excludes the loss on early retirement of debt and related costs, and their related tax effects for the third quarter ended September 30, 2023. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table IX of this release. A reconciliation of earnings per common share to adjusted earnings per common share is presented in table X of this release.

For the nine months ended September 30, 2023, revenue increased 5.3% to $5,005.2 million, compared to $4,752.1 million for the same period, prior year. Income from operations increased 39.3% to $440.6 million for the nine months ended September 30, 2023, compared to $316.4 million for the same period, prior year. For the nine months ended September 30, 2023, income from operations included $1.2 million of other operating income, compared to $23.6 million for the same period, prior year. The other operating income for the nine months ended September 30, 2022, was principally related to the recognition of payments received under the Provider Relief Fund. Net income increased 48.4% to $237.9 million for the nine months ended September 30, 2023, compared to $160.3 million for the same period, prior year. Adjusted EBITDA increased 26.0% to $627.4 million for the nine months ended September 30, 2023, compared to $498.0 million for the same period, prior year. Earnings per common share increased 52.8% to $1.55 for the nine months ended September 30, 2023, compared to $1.01 for the same period, prior year. Adjusted earnings per common share increased 60.8% to $1.63 for the nine months ended September 30, 2023, compared to $1.01 for the same quarter, prior year. Adjusted earnings per common share excludes the loss on early retirement of debt and related costs, and their related tax effects for the nine months ended September 30, 2023. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table IX of this release. A reconciliation of earnings per common share to adjusted earnings per common share is presented in table X of this release.

Company Overview

Select Medical is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States based on number of facilities.   Select Medical’s reportable segments include the critical illness recovery hospital segment, the rehabilitation hospital segment, the outpatient rehabilitation segment, and the Concentra segment. As of September 30, 2023, Select Medical operated 107 critical illness recovery hospitals in 28 states, 33 rehabilitation hospitals in 13 states, 1,946 outpatient rehabilitation clinics in 39 states and the District of Columbia, and 539 occupational health centers in 41 states. At September 30, 2023, Select Medical had operations in 46 states and the District of Columbia. Information about Select Medical is available at www.selectmedical.com.

Critical Illness Recovery Hospital Segment

For the third quarter ended September 30, 2023, revenue for the critical illness recovery hospital segment increased 7.4% to $563.6 million, compared to $524.6 million for the same quarter, prior year. Adjusted EBITDA for the critical illness recovery hospital segment increased 321.0% to $46.4 million for the third quarter ended September 30, 2023, compared to $11.0 million for the same quarter, prior year. The Adjusted EBITDA margin for the critical illness recovery hospital segment was 8.2% for the third quarter ended September 30, 2023, compared to 2.1% for the same quarter, prior year. Certain critical illness recovery hospital key statistics are presented in table VII of this release for the third quarters ended September 30, 2023 and 2022.

For the nine months ended September 30, 2023, revenue for the critical illness recovery hospital segment increased 3.6% to $1,732.6 million, compared to $1,672.2 million for the same period, prior year. Adjusted EBITDA for the critical illness recovery hospital segment increased 181.5% to $188.6 million for the nine months ended September 30, 2023, compared to $67.0 million for the same period, prior year. The Adjusted EBITDA margin for the critical illness recovery hospital segment was 10.9% for the nine months ended September 30, 2023, compared to 4.0% for the same period, prior year. Certain critical illness recovery hospital key statistics are presented in table VIII of this release for the nine months ended September 30, 2023 and 2022.

Rehabilitation Hospital Segment

For the third quarter ended September 30, 2023, revenue for the rehabilitation hospital segment increased 7.7% to $247.1 million, compared to $229.4 million for the same quarter, prior year. Adjusted EBITDA for the rehabilitation hospital segment increased 7.7% to $53.6 million for the third quarter ended September 30, 2023, compared to $49.8 million for the same quarter, prior year. The Adjusted EBITDA margin for the rehabilitation hospital segment was 21.7% for each of the third quarters ended September 30, 2023 and 2022. Certain rehabilitation hospital key statistics are presented in table VII of this release for the third quarters ended September 30, 2023 and 2022.

For the nine months ended September 30, 2023, revenue for the rehabilitation hospital segment increased 6.0% to $719.4 million, compared to $678.9 million for the same period, prior year. Adjusted EBITDA for the rehabilitation hospital segment increased 9.5% to $155.5 million for the nine months ended September 30, 2023, compared to $142.0 million for the same period, prior year. The Adjusted EBITDA margin for the rehabilitation hospital segment was 21.6% for the nine months ended September 30, 2023, compared to 20.9% for the same period, prior year. Certain rehabilitation hospital key statistics are presented in table VIII of this release for the nine months ended September 30, 2023 and 2022.

Outpatient Rehabilitation Segment

For the third quarter ended September 30, 2023, revenue for the outpatient rehabilitation segment increased 2.4% to $291.8 million, compared to $285.0 million for the same quarter, prior year. Adjusted EBITDA for the outpatient rehabilitation segment increased 2.5% to $26.3 million for the third quarter ended September 30, 2023, compared to $25.7 million for the same quarter, prior year. The Adjusted EBITDA margin for the outpatient rehabilitation segment was 9.0% for the third quarters ended September 30, 2023 and 2022. Certain outpatient rehabilitation key statistics are presented in table VII of this release for the third quarters ended September 30, 2023 and 2022.

For the nine months ended September 30, 2023, revenue for the outpatient rehabilitation segment increased 5.5% to $890.7 million, compared to $844.2 million for the same period, prior year. Adjusted EBITDA for the outpatient rehabilitation segment increased 4.1% to $89.4 million for the nine months ended September 30, 2023, compared to $85.9 million for the same period, prior year. The Adjusted EBITDA margin for the outpatient rehabilitation segment was 10.0% for the nine months ended September 30, 2023, compared to 10.2% for the same period, prior year. Certain outpatient rehabilitation key statistics are presented in table VIII of this release for the nine months ended September 30, 2023 and 2022.

Concentra Segment

For the third quarter ended September 30, 2023, revenue for the Concentra segment increased 6.6% to $474.0 million, compared to $444.6 million for the same quarter, prior year. Adjusted EBITDA for the Concentra segment increased 9.9% to $98.9 million for the third quarter ended September 30, 2023, compared to $90.0 million for the same quarter, prior year. The Adjusted EBITDA margin for the Concentra segment was 20.9% for the third quarter ended September 30, 2023, compared to 20.2% for the same quarter, prior year. Certain Concentra key statistics are presented in table VII of this release for the third quarters ended September 30, 2023 and 2022.

For the nine months ended September 30, 2023, revenue for the Concentra segment increased 6.7% to $1,397.3 million, compared to $1,309.4 million for the same period, prior year. Adjusted EBITDA for the Concentra segment increased 7.7% to $293.0 million for the nine months ended September 30, 2023, compared to $272.1 million for the same period, prior year. The Adjusted EBITDA margin for the Concentra segment was 21.0% for the nine months ended September 30, 2023, compared to 20.8% for the same period, prior year. Certain Concentra key statistics are presented in table VIII of this release for the nine months ended September 30, 2023 and 2022.

Dividend

On November 2, 2023, Select Medical’s Board of Directors declared a cash dividend of $0.125 per share. The dividend will be payable on or about November 28, 2023, to stockholders of record as of the close of business on November 15, 2023.

There is no assurance that future dividends will be declared. The declaration and payment of dividends in the future are at the discretion of Select Medical’s Board of Directors after taking into account various factors, including, but not limited to, Select Medical’s financial condition, operating results, available cash and current and anticipated cash needs, the terms of Select Medical’s indebtedness, and other factors Select Medical’s Board of Directors may deem to be relevant.

Stock Repurchase Program

The Board of Directors of Select Medical has authorized a common stock repurchase program to repurchase up to $1.0 billion worth of shares of its common stock. The common stock repurchase program will remain in effect until December 31, 2025, unless further extended or earlier terminated by the Board of Directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Select Medical deems appropriate. Select Medical funds this program with cash on hand and borrowings under its revolving credit facility.

Select Medical did not repurchase shares under its authorized stock repurchase program during the nine months ended September 30, 2023. Since the inception of the common stock repurchase program through September 30, 2023, Select Medical has repurchased 48,234,823 shares at a cost of approximately $600.3 million, or $12.45 per share, which includes transaction costs.

Financing Transactions

On July 31, 2023, the Company entered into Amendment No. 8 to the Select credit agreement. Amendment No. 8 provides for a new tranche of term loans in an aggregate principal amount of $2,103.0 million to replace the existing term loans and a $710.0 million new revolving credit facility to replace the $650.0 million existing revolving credit facility. The term loans and the extended revolving credit facility will mature on March 6, 2027, with an early springing maturity 90 days prior to the senior notes maturity, triggered if more than $300.0 million of senior notes remain outstanding on May 15, 2026. The term loans have an interest rate of Term SOFR plus 3.00% and the revolving credit facility has an interest rate of Adjusted Term SOFR (which includes a 0.10% credit spread adjustment) plus 2.50%, in each case, subject to a leverage-based pricing grid. During the three months ended September 30, 2023, the Company recognized a $14.7 million loss on early retirement of debt as a result of the amendment to the Select credit agreement.

On August 31, 2023, the Company entered into Amendment No. 9 to the Select credit agreement. Amendment No. 9 increased the revolving credit facility commitments from $710.0 million to $770.0 million.

Business Outlook

We are maintaining our business outlook for 2023 with expected revenue to be in the range of $6.55 billion to $6.7 billion, expected Adjusted EBITDA in the range of $795.0 million to $825.0 million, and fully diluted earnings per share to be in the range of $1.77 to $1.94. Select Medical expects adjusted earnings per share, which was revised to exclude the actual tax-effected loss on early retirement of debt, to be in the range of $1.85 to $2.02. Reconciliations of full year 2023 Adjusted EBITDA expectations to net income and adjusted earnings per share to fully diluted earnings per share are presented in table XI of this release.

Conference Call

Select Medical will host a conference call regarding its third quarter result and its business outlook on Friday, November 3, 2023, at 9:00am ET. The conference call will be a live webcast and can be accessed at Select Medical Holdings Corporation’s website at www.selectmedicalholdings.com. A replay of the webcast will be available shortly after the call through the same link.

For listeners wishing to dial-in via telephone, or participate in the question and answer session, you may pre-register for the call at Select Medical Earnings Call Registration to obtain your dial-in number and unique passcode.

*   *   *   *   *

Certain statements contained herein that are not descriptions of historical facts are “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995), including statements related to Select Medical’s 2023 and long-term business outlook. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements due to factors including the following:

  • adverse economic conditions including an inflationary environment could cause us to continue to experience increases in the prices of labor and other costs of doing business resulting in a negative impact on our business, operating results, cash flows, and financial condition;
  • shortages in qualified nurses, therapists, physicians, or other licensed providers, and/or the inability to attract or retain qualified healthcare professionals could limit our ability to staff our facilities;
  • shortages in qualified health professionals could cause us to increase our dependence on contract labor, increase our efforts to recruit and train new employees, and expand upon our initiatives to retain existing staff, which could increase our operating costs significantly;
  • the continuing effects of the COVID-19 pandemic including, but not limited to, the prolonged disruption to the global financial markets, increased operational costs due to recessionary pressures and labor costs, additional measures taken by government authorities and the private sector to limit the spread of COVID-19, and further legislative and regulatory actions which impact healthcare providers, including actions that may impact the Medicare program;
  • changes in government reimbursement for our services and/or new payment policies may result in a reduction in revenue, an increase in costs, and a reduction in profitability;
  • the failure of our Medicare-certified long term care hospitals or inpatient rehabilitation facilities to maintain their Medicare certifications may cause our revenue and profitability to decline;
  • the failure of our Medicare-certified long term care hospitals and inpatient rehabilitation facilities operated as “hospitals within hospitals” to qualify as hospitals separate from their host hospitals may cause our revenue and profitability to decline;
  • a government investigation or assertion that we have violated applicable regulations may result in sanctions or reputational harm and increased costs;
  • acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources, or expose us to unforeseen liabilities;
  • our plans and expectations related to our acquisitions and our ability to realize anticipated synergies;
  • private third-party payors for our services may adopt payment policies that could limit our future revenue and profitability;
  • the failure to maintain established relationships with the physicians in the areas we serve could reduce our revenue and profitability;
  • competition may limit our ability to grow and result in a decrease in our revenue and profitability;
  • the loss of key members of our management team could significantly disrupt our operations;
  • the effect of claims asserted against us could subject us to substantial uninsured liabilities;
  • a security breach of our or our third-party vendors’ information technology systems may subject us to potential legal and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 or the Health Information Technology for Economic and Clinical Health Act; and
  • other factors discussed from time to time in our filings with the Securities and Exchange Commission (the “SEC”), including factors discussed under the heading “Risk Factors” of our quarterly reports on Form 10-Q and in our annual report on Form 10-K for the year ended December 31, 2022.

Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.

Investor inquiries:
Joel T. Veit
Senior Vice President and Treasurer
717-972-1100
[email protected]

I.  Condensed Consolidated Statements of Operations

For the Three Months Ended September 30, 2022 and 2023

(In thousands, except per share amounts, unaudited)




2022


2023


% Change

Revenue


$             1,567,794


$             1,665,694


6.2 %

Costs and expenses:







Cost of services, exclusive of depreciation and amortization


1,393,817


1,442,509


3.5

General and administrative


39,491


41,316


4.6

Depreciation and amortization


51,459


52,394


1.8

Total costs and expenses


1,484,767


1,536,219


3.5

Other operating income


8,440


485


N/M

Income from operations


91,467


129,960


42.1

Other income and expense:







Loss on early retirement of debt



(14,692)


N/M

Equity in earnings of unconsolidated subsidiaries


8,084


11,561


43.0

Interest expense


(45,204)


(50,271)


11.2

Income before income taxes


54,347


76,558


40.9

Income tax expense


16,221


15,742


(3.0)

Net income


38,126


60,816


59.5

Less: Net income attributable to non-controlling interests


10,960


12,636


15.3

Net income attributable to Select Medical


$                  27,166


$                  48,180


77.4 %

Basic and diluted earnings per common share:(1)


$                       0.21


$                       0.38





(1)

Refer to table III for calculation of earnings per common share.

N/M

Not meaningful

II.  Condensed Consolidated Statements of Operations

For the Nine Months Ended September 30, 2022 and 2023

(In thousands, except per share amounts, unaudited)




2022


2023


% Change

Revenue


$             4,752,082


$             5,005,202


5.3 %

Costs and expenses:







Cost of services, exclusive of depreciation and amortization


4,191,377


4,284,931


2.2

General and administrative


114,272


126,103


10.4

Depreciation and amortization


153,579


154,758


0.8

Total costs and expenses


4,459,228


4,565,792


2.4

Other operating income


23,565


1,211


N/M

Income from operations


316,419


440,621


39.3

Other income and expense:







Loss on early retirement of debt



(14,692)


N/M

Equity in earnings of unconsolidated subsidiaries


19,648


30,618


55.8

Interest expense


(121,770)


(147,839)


21.4

Income before income taxes


214,297


308,708


44.1

Income tax expense


53,983


70,775


31.1

Net income


160,314


237,933


48.4

Less: Net income attributable to non-controlling interests


28,824


40,711


41.2

Net income attributable to Select Medical


$                131,490


$                197,222


50.0 %

Basic and diluted earnings per common share:(1)


$                       1.01


$                       1.55





(1)

Refer to table III for calculation of earnings per common share.

N/M

Not meaningful



III. Earnings per Share
For the Three and Nine Months Ended September 30, 2022 and 2023
(In thousands, except per share amounts, unaudited)

Select Medical’s capital structure includes common stock and unvested restricted stock awards. To compute earnings per share (“EPS”), Select Medical applies the two-class method because its unvested restricted stock awards are participating securities which are entitled to participate equally with its common stock in undistributed earnings.

The following table sets forth the net income attributable to Select Medical, its common shares outstanding, and its participating securities outstanding for the three and nine months ended September 30, 2022 and 2023:



Basic and Diluted EPS



Three Months Ended

September 30,


Nine Months Ended

September 30,



2022


2023


2022


2023

Net income


$         38,126


$         60,816


$       160,314


$       237,933

Less: net income attributable to non-controlling interests


10,960


12,636


28,824


40,711

Net income attributable to Select Medical


27,166


48,180


131,490


197,222

Less: net income attributable to participating securities


992


1,722


4,588


7,155

Net income attributable to common shares


$         26,174


$         46,458


$       126,902


$       190,067

The following tables set forth the computation of EPS under the two-class method for the three and nine months ended September 30, 2022 and 2023:



Three Months Ended September 30,



2022



2023



Net Income
Allocation


Shares(1)


Basic and
Diluted EPS



Net Income
Allocation


Shares(1)


Basic and
Diluted EPS



(in thousands, except for per share amounts)

Common shares


$         26,174


122,193


$              0.21



$            46,458


123,400


$              0.38

Participating securities


992


4,631


$              0.21



1,722


4,574


$              0.38

Total


$         27,166







$            48,180







Nine Months Ended September 30,



2022



2023



Net Income
Allocation


Shares(1)


Basic and
Diluted EPS



Net Income
Allocation


Shares(1)


Basic and
Diluted EPS



(in thousands, except for per share amounts)

Common shares


$       126,902


125,341


$              1.01



$          190,067


122,865


$              1.55

Participating securities


4,588


4,532


$              1.01



7,155


4,625


$              1.55

Total


$       131,490







$          197,222








(1)

Represents the weighted average share count outstanding during the period.

IV.  Condensed Consolidated Balance Sheets

(In thousands, unaudited)




December 31, 2022


September 30, 2023

Assets





Current Assets:





Cash and cash equivalents


$                       97,906


$                       77,440

Accounts receivable


941,312


944,219

Other current assets


232,095


254,428

Total Current Assets


1,271,313


1,276,087

Operating lease right-of-use assets


1,169,740


1,180,907

Property and equipment, net


1,001,440


1,006,842

Goodwill


3,484,200


3,504,654

Identifiable intangible assets, net


351,662


336,639

Other assets


386,938


378,879

Total Assets


$                 7,665,293


$                 7,684,008

Liabilities and Equity





Current Liabilities:





Payables and accruals


$                     874,016


$                     888,377

Current operating lease liabilities


236,784


242,594

Current portion of long-term debt and notes payable


44,351


35,085

Total Current Liabilities


1,155,151


1,166,056

Non-current operating lease liabilities


1,008,394


1,019,185

Long-term debt, net of current portion


3,835,211


3,695,244

Non-current deferred tax liability


169,793


146,919

Other non-current liabilities


106,137


106,216

Total Liabilities


6,274,686


6,133,620

Redeemable non-controlling interests


34,043


26,999

Total equity


1,356,564


1,523,389

Total Liabilities and Equity


$                 7,665,293


$                 7,684,008

V.  Condensed Consolidated Statements of Cash Flows

For the Three Months Ended September 30, 2022 and 2023

(In thousands, unaudited)




2022


2023

Operating activities





Net income


$                       38,126


$                       60,816

Adjustments to reconcile net income to net cash provided by operating
activities:





Distributions from unconsolidated subsidiaries


5,752


1,055

Depreciation and amortization


51,459


52,394

Provision for expected credit losses


(152)


340

Equity in earnings of unconsolidated subsidiaries


(8,084)


(11,561)

Loss on extinguishment of debt



175

Gain (loss) on sale or disposal of assets


(117)


16

Stock compensation expense


10,187


11,483

Amortization of debt discount, premium and issuance costs


573


725

Deferred income taxes


(5,115)


(6,173)

Changes in operating assets and liabilities, net of effects of business
combinations:





Accounts receivable


12,745


20,121

Other current assets


5,051


(11,279)

Other assets


8,375


1,556

Accounts payable and accrued expenses


(19,008)


(3,330)

Government advances


(5,529)


Net cash provided by operating activities


94,263


116,338

Investing activities





Business combinations, net of cash acquired


(2,786)


(12,750)

Purchases of property, equipment, and other assets


(41,942)


(50,198)

Investment in businesses


(10,333)


(74)

Proceeds from sale of assets


50


4

Net cash used in investing activities


(55,011)


(63,018)

Financing activities





Borrowings on revolving facilities


280,000


200,000

Payments on revolving facilities


(250,000)


(205,000)

Proceeds from term loans



2,092,232

Payments on term loans



(2,108,694)

Borrowings of other debt


3,372


8,551

Principal payments on other debt


(8,291)


(11,925)

Dividends paid to common stockholders


(15,893)


(16,035)

Repurchase of common stock


(14,991)


(9,544)

Increase (decrease) in overdrafts


1,964


(1,500)

Proceeds from issuance of non-controlling interests


141


5,651

Distributions to and purchases of non-controlling interests


(22,000)


(30,783)

Net cash used in financing activities


(25,698)


(77,047)

Net increase (decrease) in cash and cash equivalents


13,554


(23,727)

Cash and cash equivalents at beginning of period


94,669


101,167

Cash and cash equivalents at end of period


$                     108,223


$                       77,440

Supplemental information





Cash paid for interest, excluding amounts received of $6,129 and $22,069
under interest rate cap contract


$                       69,238


$                       88,116

Cash paid for taxes


8,421


35,747

VI.  Condensed Consolidated Statements of Cash Flows

For the Nine Months Ended September 30, 2022 and 2023

(In thousands, unaudited)




2022


2023

Operating activities





Net income


$                     160,314


$                     237,933

Adjustments to reconcile net income to net cash provided by operating
activities:





Distributions from unconsolidated subsidiaries


16,892


9,896

Depreciation and amortization


153,579


154,758

Provision for expected credit losses


(41)


1,101

Equity in earnings of unconsolidated subsidiaries


(19,648)


(30,618)

Loss on extinguishment of debt



175

Gain on sale or disposal of assets


(1,593)


(7)

Stock compensation expense


27,956


31,991

Amortization of debt discount, premium and issuance costs


1,696


1,899

Deferred income taxes


(7,080)


(17,049)

Changes in operating assets and liabilities, net of effects of business
combinations:





Accounts receivable


(19,686)


(3,014)

Other current assets


2,923


(17,276)

Other assets


9,650


7,028

Accounts payable and accrued expenses


30,167


25,799

Government advances


(82,848)


Net cash provided by operating activities


272,281


402,616

Investing activities





Business combinations, net of cash acquired


(22,027)


(20,482)

Purchases of property, equipment, and other assets


(135,119)


(168,597)

Investment in businesses


(17,323)


(9,874)

Proceeds from sale of assets


5,364


60

Net cash used in investing activities


(169,105)


(198,893)

Financing activities





Borrowings on revolving facilities


845,000


635,000

Payments on revolving facilities


(625,000)


(740,000)

Proceeds from term loans



2,092,232

Payments on term loans



(2,108,694)

Borrowings of other debt


20,866


30,849

Principal payments on other debt


(25,165)


(38,298)

Dividends paid to common stockholders


(48,692)


(47,856)

Repurchase of common stock


(193,614)


(11,050)

Decrease in overdrafts


(9,091)


(1,967)

Proceeds from issuance of non-controlling interests


7,096


20,463

Distributions to and purchases of non-controlling interests


(40,663)


(54,868)

Net cash used in financing activities


(69,263)


(224,189)

Net increase (decrease) in cash and cash equivalents


33,913


(20,466)

Cash and cash equivalents at beginning of period


74,310


97,906

Cash and cash equivalents at end of period


$                     108,223


$                       77,440

Supplemental information





Cash paid for interest, excluding amounts received of $6,232 and $60,353
under the interest rate cap contract


$                     143,455


$                     221,697

Cash paid for taxes


24,844


78,502

VII.  Key Statistics

For the Three Months Ended September 30, 2022, and 2023

(unaudited)




2022


2023


% Change

Critical Illness Recovery Hospital







Number of hospitals operated – end of period(a)


105


107



Revenue (,000)


$      524,584


$      563,628


7.4 %

Number of patient days(b)(c)


278,137


267,910


(3.7) %

Number of admissions(b)(d)


9,056


8,736


(3.5) %

Revenue per patient day(b)(e)


$          1,878


$          2,095


11.6 %

Occupancy rate(b)(f)


67 %


64 %


(4.5) %

Adjusted EBITDA (,000)


$        11,013


$        46,362


321.0 %

Adjusted EBITDA margin


2.1 %


8.2 %



Rehabilitation Hospital







Number of hospitals operated – end of period(a)


31


33



Revenue (,000)


$      229,387


$      247,101


7.7 %

Number of patient days(b)(c)


109,076


112,095


2.8 %

Number of admissions(b)(d)


7,517


7,840


4.3 %

Revenue per patient day(b)(e)


$          1,931


$          2,025


4.9 %

Occupancy rate(b)(f)


85 %


84 %


(1.2) %

Adjusted EBITDA (,000)


$        49,772


$        53,626


7.7 %

Adjusted EBITDA margin


21.7 %


21.7 %



Outpatient Rehabilitation







Number of clinics operated – end of period(a)


1,933


1,946



Working days(g)


64


63



Revenue (,000)


$      284,993


$      291,804


2.4 %

Number of visits(b)(h)


2,404,868


2,627,362


9.3 %

Revenue per visit(b)(i)


$             103


$             100


(2.9) %

Adjusted EBITDA (,000)


$        25,715


$        26,346


2.5 %

Adjusted EBITDA margin


9.0 %


9.0 %



Concentra







Number of centers operated – end of period(b)


519


539



Working days(g)


64


63



Revenue (,000)


$      444,576


$      473,964


6.6 %

Number of visits(b)(h)


3,273,031


3,281,042


0.2 %

Revenue per visit(b)(i)


$             128


$             136


6.3 %

Adjusted EBITDA (,000)


$        90,025


$        98,907


9.9 %

Adjusted EBITDA margin


20.2 %


20.9 %







(a)

Includes managed locations.

(b)

Excludes managed locations. For purposes of the Concentra segment, onsite clinics are excluded.

(c)

Each patient day represents one patient occupying one bed for one day during the periods presented.

(d)

Represents the number of patients admitted to Select Medical’s hospitals during the periods presented.

(e)

Represents the average amount of revenue recognized for each patient day. Revenue per patient day is calculated by dividing patient service revenues, excluding revenues from certain other ancillary and outpatient services provided at Select Medical’s hospitals, by the total number of patient days.

(f)

Represents the portion of our hospitals being utilized for patient care during the periods presented. Occupancy rate is calculated using the number of patient days, as presented above, divided by the total number of bed days available during the period. Bed days available is derived by adding the daily number of available licensed beds for each of the periods presented.

(g)

Represents the number of days in which normal business operations were conducted during the periods presented.

(h)

Represents the number of visits in which patients were treated at Select Medical’s outpatient rehabilitation clinics and Concentra centers during the periods presented. COVID-19 screening and testing services provided by our Concentra segment are not included in these figures.

(i)

Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated by dividing patient service revenue, excluding revenues from certain other ancillary services, by the total number of visits. For purposes of this computation for the Concentra segment, patient service revenue does not include onsite clinics or revenues generated from COVID-19 screening and testing services.

VIII.  Key Statistics

For the Nine Months Ended September 30, 2022, and 2023

(unaudited)




2022


2023


% Change

Critical Illness Recovery Hospital







Number of hospitals operated – end of period(a)


105


107



Revenue (,000)


$    1,672,247


$    1,732,645


3.6 %

Number of patient days(b)(c)


840,487


831,022


(1.1) %

Number of admissions(b)(d)


27,319


27,099


(0.8) %

Revenue per patient day(b)(e)


$            1,981


$            2,076


4.8 %

Occupancy rate(b)(f)


68 %


68 %


0.0 %

Adjusted EBITDA (,000)


$          66,999


$        188,631


181.5 %

Adjusted EBITDA margin


4.0 %


10.9 %



Rehabilitation Hospital







Number of hospitals operated – end of period(a)


31


33



Revenue (,000)


$        678,908


$        719,419


6.0 %

Number of patient days(b)(c)


321,690


330,142


2.6 %

Number of admissions(b)(d)


22,149


23,363


5.5 %

Revenue per patient day(b)(e)


$            1,934


$            2,001


3.5 %

Occupancy rate(b)(f)


85 %


84 %


(1.2) %

Adjusted EBITDA (,000)


$        141,996


$        155,531


9.5 %

Adjusted EBITDA margin


20.9 %


21.6 %



Outpatient Rehabilitation







Number of clinics operated – end of period(a)


1,933


1,946



Working days(g)


192


191



Revenue (,000)


$        844,191


$        890,679


5.5 %

Number of visits(b)(h)


7,165,866


7,984,622


11.4 %

Revenue per visit(b)(i)


$               103


$               100


(2.9) %

Adjusted EBITDA (,000)


$          85,912


$          89,395


4.1 %

Adjusted EBITDA margin


10.2 %


10.0 %



Concentra







Number of centers operated – end of period(b)


519


539



Working days(g)


192


191



Revenue (,000)


$    1,309,356


$    1,397,341


6.7 %

Number of visits(b)(h)


9,604,441


9,766,881


1.7 %

Revenue per visit(b)(i)


$               127


$               135


6.3 %

Adjusted EBITDA (,000)


$        272,101


$        293,046


7.7 %

Adjusted EBITDA margin


20.8 %


21.0 %







(a)

Includes managed locations.

(b)

Excludes managed locations. For purposes of the Concentra segment, onsite clinics are excluded.

(c)

Each patient day represents one patient occupying one bed for one day during the periods presented.

(d)

Represents the number of patients admitted to Select Medical’s hospitals during the periods presented.

(e)

Represents the average amount of revenue recognized for each patient day. Revenue per patient day is calculated by dividing patient service revenues, excluding revenues from certain other ancillary and outpatient services provided at Select Medical’s hospitals, by the total number of patient days.

(f)

Represents the portion of our hospitals being utilized for patient care during the periods presented. Occupancy rate is calculated using the number of patient days, as presented above, divided by the total number of bed days available during the period. Bed days available is derived by adding the daily number of available licensed beds for each of the periods presented.

(g)

Represents the number of days in which normal business operations were conducted during the periods presented.

(h)

Represents the number of visits in which patients were treated at Select Medical’s outpatient rehabilitation clinics and Concentra centers during the periods presented. COVID-19 screening and testing services provided by our Concentra segment are not included in these figures.

(i)

Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated by dividing patient service revenue, excluding revenues from certain other ancillary services, by the total number of visits. For purposes of this computation for the Concentra segment, patient service revenue does not include onsite clinics or revenues generated from COVID-19 screening and testing services.



IX. Net Income to Adjusted EBITDA Reconciliation
For the Three and Nine Months Ended September 30, 2022 and 2023 
(In thousands, unaudited)

The presentation of Adjusted EBITDA is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA is used by management to evaluate financial performance and determine resource allocation for each of Select Medical’s segments. Adjusted EBITDA is not a measure of financial performance under accounting principles generally accepted in the United States of America (“GAAP”). Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to, or substitute for, net income, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying definitions, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies.

The following table reconciles net income to Adjusted EBITDA for Select Medical. Adjusted EBITDA is used by Select Medical to report its segment performance. Adjusted EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries.


Three Months Ended

September 30,



Nine Months Ended

September 30,



2022


2023




2022


2023

Net income


$         38,126


$         60,816




$       160,314


$       237,933

Income tax expense


16,221


15,742




53,983


70,775

Interest expense


45,204


50,271




121,770


147,839

Equity in earnings of unconsolidated subsidiaries


(8,084)


(11,561)




(19,648)


(30,618)

Loss on early retirement of debt



14,692





14,692

Income from operations


91,467


129,960




316,419


440,621

Stock compensation expense:











Included in general and administrative


8,000


9,425




21,995


26,383

Included in cost of services


2,187


2,058




5,961


5,607

Depreciation and amortization


51,459


52,394




153,579


154,758

Adjusted EBITDA


$       153,113


$       193,837




$       497,954


$       627,369












Critical illness recovery hospital


$         11,013


$         46,362




$         66,999


$       188,631

Rehabilitation hospital


49,772


53,626




141,996


155,531

Outpatient rehabilitation


25,715


26,346




85,912


89,395

Concentra


90,025


98,907




272,101


293,046

Other(a)


(23,412)


(31,404)




(69,054)


(99,234)

Adjusted EBITDA


$       153,113


$       193,837




$       497,954


$       627,369





(a)

Other primarily includes general and administrative costs and other operating income, as discussed further above.



X. Reconciliation of Earnings per Common Share to Adjusted Earnings per Common Share
For the Three and Nine Months Ended September 30, 2022 and 2023
(In thousands, except per share amounts, unaudited)

Adjusted net income attributable to common shares and adjusted earnings per common share are not measures of financial performance under GAAP. Items excluded from adjusted net income attributable to common shares and adjusted earnings per common share are significant components in understanding and assessing financial performance. Select Medical believes that the presentation of adjusted net income attributable to common shares and adjusted earnings per common share are important to investors because they are reflective of the financial performance of Select Medical’s ongoing operations and provide better comparability of its results of operations between periods. Adjusted net income attributable to common shares and adjusted earnings per common share should not be considered in isolation or as alternatives to, or substitutes for, net income, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because adjusted net income attributable to common shares and adjusted earnings per common share are not measurements determined in accordance with GAAP and are thus susceptible to varying calculations, adjusted net income attributable to common shares and adjusted earnings per common share as presented may not be comparable to other similarly titled measures of other companies.

The following tables reconcile net income attributable to common shares and earnings per common share on a fully diluted basis to adjusted net income attributable to common shares and adjusted earnings per common share on a fully diluted basis.


Three Months Ended September 30,


2022


Per Share(a)


2023


Per Share(a)

Net income attributable to common shares(a)

$          26,174


$               0.21


$          46,458


$               0.38

Adjustments:(b)








Loss on early retirement of debt, net of tax



10,022


0.08

Adjusted net income attributable to common shares

$          26,174


$               0.21


$          56,480


$               0.46


Nine Months Ended September 30,


2022


Per Share(a)


2023


Per Share(a)

Net income attributable to common shares(a)

$        126,902


$               1.01


$        190,067


$               1.55

Adjustments:(b)








Loss on early retirement of debt, net of tax



10,016


0.08

Adjusted net income attributable to common shares

$        126,902


$               1.01


$        200,083


$               1.63





(a)

Net income attributable to common shares and earnings per common share are calculated based on the weighted average common shares outstanding, as presented in table III.

(b)

Adjustments to net income attributable to common shares include estimated income tax and non-controlling interest impacts and are calculated based on the diluted weighted average common shares outstanding. The estimated income tax impact, which is determined using tax rates based on the nature of the adjustment and the jurisdiction in which the adjustment occurred, includes both current and deferred income tax expense or benefit.



XI. Net Income to Adjusted EBITDA and Earnings per Share to Adjusted Earnings per Share Reconciliations
Business Outlook for the Year Ending December 31, 2023
(In millions, unaudited)

The following are reconciliations of full year 2023 Adjusted EBITDA and adjusted income per common share expectations as computed at the low and high points of the range to the closest comparable GAAP financial measure. Refer to tables IX and table X for discussion of Select Medical’s use of Adjusted EBITDA and adjusted income per common share in evaluating financial performance. Refer to table IX for the definition of Adjusted EBITDA and a discussion of Select Medical’s use of Adjusted EBITDA in evaluating financial performance. Each item presented in the below table is an estimation of full year 2023 expectations.


Range

Non-GAAP Measure Reconciliation

Low


High

Net income attributable to Select Medical

$                            227


$                            249

Net income attributable to non-controlling interests

53


56

Net income

280


305

Income tax expense

89


97

Interest expense

196


196

Equity in earnings of unconsolidated subsidiaries

(39)


(42)

Loss on early retirement of debt

15


15

Income from operations

541


571

Stock compensation expense

43


43

Depreciation and amortization

211


211

Adjusted EBITDA

$                            795


$                            825




Range

Non-GAAP Measure Reconciliation

Low


High

Diluted earnings per share

$                           1.77


$                           1.94

Adjustments:




Loss on early retirement of debt, net of tax

0.08


0.08

Adjusted earnings per share

$                           1.85


$                           2.02

   

SOURCE Select Medical Holdings Corporation



READ SOURCE

This website uses cookies. By continuing to use this site, you accept our use of cookies.